Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0007097 (carcinoma)
 152,788 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Estramustine phosphate (Estracyt), a combination of estradiol and nitrogen mustard given to males with prostatic carcinoma, had the same effect on serum lipids, lipoproteins, and serum phosphoglyceride fatty acid composition as ethynyl estradiol (Etivex). The characteristic effects on serum lipids caused by both drugs, i.e., a reduction in serum cholesterol and an increase in serum phospholipids, were apparently expressions for reduced low density lipoproteins and increased alpha-lipoproteins. Serum lecithin fatty acid composition revealed during the administration of both drugs a characteristic increase in palmitic acid (16:0) and a decrease in stearic acid (18:0), interpreted as evidence for a cholestatic, although subclinical, liver involvement. Similar changes have earlier been revealed in women given ethynyl estradiol; however, the increase in serum triglycerides and very low density lipoprotein cholesterol in young women was not duplicated in aged males with prostatic carcinoma. Furthermore, in aged males, the administration of these estrogens did not change carbohydrate metabolism but did produce an increase in adipose tissue lipoprotein lipase.
 ...
PMID:Treatment of oral estramustine phosphate (Estracyt) in prostatic carcinoma: influences on lipid and carbohydrate metabolism. 59 Dec 68

Potent inhibition of human prostatic carcinoma tissue acid phosphatase by N,N-d-di-2-chloroethylaminophenol (AMOH) and N,N-p-di-2-chloroethylaminophenyl phosphate (AMPh) is described. Certain other difunctional nitrogen mustards were also inhibitory but N,N-p-di-2hydroxyethylaminophenol, the non-alkylating fully hydrolysed product from AMOH, was not. Inactivation of the enzyme by AMPh was progressive with time, showed apparent first order reaction kinetics and was not reversed by extensive dialysis. The results suggest that the inability of the enzyme to catalyse the hydrolysis of AMPh was due to inhibition in the presence of AMPh, possibly involving an alkylating mechanism. The implications for possible chemotherapy with AMPh are discussed.
 ...
PMID:Inhibition of human prostatic tumour acid phosphatase by N,N-p-di-2-chloroethylaminophenol, N,N-p-di-2-chloroethylaminophenyl phosphate and other difunctional nitrogen mustards. 63 Jun 40

Use of a liquid nitrogen container for convenient transport of frozen mammary carcinoma tissue for hormone-receptor assays is described. The container can be used in dry or wet mode and is appropriate for all types of transport, including air. Experience shows a significantly higher incidence of positive tests on specimens transported by this means than on specimens transported in dry ice.
 ...
PMID:Increased incidence of positive tests for estrogen binding in mammary carcinoma specimens transported in liquid nitrogen. 71 83

Metastasis to bone marrow, though frequently occult, is an important clinical finding. Variables which correlate with carcinoma metastatic to bone marrow were studied retrospectively in 103 patients with malignancy whose bone marrow biopsies demonstrated metastatic disease. Sixty-six patients with metastatic cancer whose bone marrow biopsies were negative, served as controls. Since no single finding was diagnostic of marrow cancer, multiple variables were analyzed by stepwise discriminate analysis program. The four parameters which strongly correlated with marrow involvement were the leukoerythroblastic blood pattern, a serum lactic dehydrogenase over 500 IU/liter, a platelet count under 100,000/microliter and bone pain. Four parameters correlated less well and included a positive bone scan, hematocrit under 30%, uric acid over 10 mg/dl and blood urea nitrogen over 25 mg/dl. These data should help the clinician select those cancer patients with a high probability of marrow involvement.
 ...
PMID:Variables predictive of bone marrow metastasis. 71 14

The serum concentrations of alphaaminonitrogen (AAN), lysine, valine and leucines were determined before and within the period of 24 hr after the administration of Trophysan (10% solution of glucose containing a mixture of aminoacids) in 100 patients with cancer (17 with gastrointestinal carcinoma, 34 with uterus carcinoma, stages I to III; 8 with breast carcinoma, stages II and III; 15 with bronchogenic carcinoma, 10 with various localizations and 15 with metastatic cancer) and in 22 patients with benign tumors. A significant decrease in the serum content of AAN, valine and lysine was noted in patients with cancer (stages I to III) at 24 hours after the administration of Trophysan. This effect was absent for the patients with benign tumors. The enhanced uptake of aminoacids found in patients with cancer is probable the result of the negative nitrogen balance associated with the malignant state.
 ...
PMID:Differences in uptake of aminoacids by patients with various forms of cancer. 74 62

We treated 21 patients with stage D prostatic adenocarcinoma who had had unsuccessful hormonal therapy with a combination of 600 mg. per M.2 per day estramustine phosphate (Estracyt) and 15 mg. per M.2 per day prednimustine (Stereocyt, Leo 1031) in daily oral doses. Estramustine is a combination of estradiol and nitrogen mustard, and alone has shown objective responses in advanced prostatic cancer. Prednimustine is an ester of chlorambucil and prednisone. The preliminary results (after 2 to 9 months of therapy) show 5 patients (24 per cent) did not benefit from the drug and 7 patients (33 per cent) are stable. These preliminary results indicate the possible advantage of adding an alkylating agent (prednimustine) to estramustine in advanced prostatic carcinoma. Currently, a national randomized trial by the National Prostatic Cancer Project is evaluating this therapeutic innovation.
 ...
PMID:Combined therapy of advanced prostatic carcinoma with estramustine and prednimustine. 83 97

Estramustine phosphate, a nor nitrogen mustard derivative of estradiol 17-beta-phosphate, was introduced in the treatment of prostatic carcinoma in 1966. Until March 1975, 466 patients have been reported on this treatment in open clinical trials: 82% of the patients were in stage IV. In 402 patients, nonresponsive to previous estrogen therapy, signigicant improvement occurred in 55%. In 64 previously untreated patients there was a favourable response in 83%. Side-effects were mainly bone marrow suppression. liver disturbance, thrombophlebitis following intravenous injection, and gastrointestinal troubles, mainly following oral administration. A prospective, randomized study comparing oral estramustine phosphate and conventional estrogen therapy in carcinoma of the prostate is in progress.
 ...
PMID:Estramustine phosphate therapy in carcinoma of the prostate. 86 98

Acute renal failure developed in nine of 78 patients who were subjected to hepatic artery ligation for nonresectable and extensive malignant tumor of the liver. Of those nine, six had hepatomas, one cholangiocarcinoma, one metastatic islet-cell carcinoma and one metastatic melanoma. Preoperative renal function as reflected in blood-urea-nitrogen and serum creatinine values was within normal limits. There were marked elevations of serum glutamic-oxalacetic transaminase and lactic dehydrogenase levels after hepatic artery ligation, an indication of massive ischemic injury of the tumor and the liver. A diagnosis of acute renal failure was established within 14 to 70 hours after hepatic artery ligation. In five patients, oliguric renal failure developed, and in four, high urinary output renal failure. In only three patients did systemic hypotension and hypovolemia precede acute renal failure. Seven of the nine patients died. Postmortem examination was done in five patients, and in only two was there evidence of renal tubular necrosis. The factors contributing to acute renal failure appear to be extensive involvement of the liver by tumor, presence of ascites and jaundice, occlusion of the portal vein and hyperuricemia. The presence of any one of the foregoing contraindicates the procedure.
 ...
PMID:Acute renal failure after ligation of the hepatic artery. 95 59

The efficacy and safety of intramuscular administration of either of the two aminoglycoside antibiotics tobramycin and gentamicin every 8 hr for seven days were compared in a prospective, randomized study of 75 elderly male patients with complicated urinary tract infections. All bacteria were sensitive to both antibiotics by the disk diffusion method. The two groups of patients (each receiving one of the two drugs) were comparable in terms of infecting microorganisms and underlying pathology of the urinary tract (mostly prostatic hyperplasia or carcinoma and urethral strictures). No patients had indwelling catheters. All patients had normal renal function (serum creatinine, less than or equal to 1.5 mg/100 ml and/or blood urea nitrogen, less than or equal to 25 mg/100 ml). In both groups 64% of the patients were cured of the infection, with cure defined as a negative urine culture result seven days after discontinuation of therapy. A statistically but not clinically significant increase in the level of serum creatinine in both groups of patients was noted after treatment.
 ...
PMID:Comparison of tobramycin and gentamicin in the treatment of complicated urinary tract infections. 97 74

Sulphur-mustard and nitrogen-mustard are known to act as carcinogens in animal experiments. A similar effect in humans was demonstrated in 245 workers previously exposed occupationally to mustard gas and followed for over 20 years. There was a statistically significant increase in malignant tumours, especially bronchial carcinoma, bladder carcinoma and leukaemia. These findings underline the need for using alkylating agents of the mustard type exclusively in the treatment of malignant neoplasms. Immunosuppression with alkylating agents in the treatment of chronic inflammatory diseases associated with a long life expectancy is no longer justified.
 ...
PMID:[Carcinogenesis due to mustard gas exposure in man, important sign for therapy with alkylating agents]. 112 60


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>